Cardiac drug-psychotropic drug update

General Hospital Psychiatry

Volumn 24, Issue 5, 2002, Pages 283-289

  Strain, James J ^a   Karim, Anwarul ^a   Caliendo, Gina ^b   Alexis, Jeffrey D ^a   Lowe III, R Sandlin ^a   Fuster, Valentin ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

Adverse drug reactions; Cardiac drugs; Drug interactions; Psychotropic drugs; Update methods

Indexed keywords

AMILORIDE; ATENOLOL; ATORVASTATIN; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC AGENT; CARVEDILOL; CLOPIDOGREL; COLESTYRAMINE; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HYDANTOIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LITHIUM; NEFAZODONE; NIFEDIPINE; NORFLUOXETINE; PHENOBARBITAL; PHENYTOIN; PROPAFENONE; PSYCHOTROPIC AGENT; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

CARDIOLOGY; CLINICAL MEDICINE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG METABOLISM; HEART ARRHYTHMIA; HUMAN; INTERNET; MYOPATHY; PANCREATITIS; PRESCRIPTION; PSYCHIATRY; PUBLICATION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 0036767687     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-8343(02)00184-6     Document Type: Article

References (17)

1. Strain J.J., Caliendo G., Alexis J.D., Lowe R.S. III, Karim A., Loigman M. Part II Cardiac drug, and psychotropic drug interactions: significance, and recommendations. Gen Hosp Psychiatry. 21:1999;408-429.
2. Hansten P.D., Horn J.R., Koda-Kimble M.A., Young L.Y. Drug interactions, and analysis, and management. Facts and comparisons. St Louis, MO, Quarterly Update. 2000.
3. Tatro D.S. Drug interaction facts. Facts, and comparisons. St. Louis, MO 1998. Quarterly Update. 1999.
4. Sewester C.S., Olin B., Hebel S.K., et al. Drug facts and comparisons. Facts and comparisons. St. Louis, MO 2000, Monthly Update July. 2001.
5. Micromedex Drugdex, Micromedex, Volume 97. 2000;Englewood, New Jersey.
6. McEvoy G.K. American Hospital Formulary Service Drug Information. 2000;American Society of Health System Pharmacists, Bethesda, MD.
7. Dear Doctor Letter. Important change in the labeling of depakote. 2001;Abbott Laboratories.
8. Mahmood I., Sahajwall C. Clinical pharmacokinetics, and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokint. 36:(4):1999;277-287.
9. Gard P.R., Mandy A., Sutcliffe M.A. Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. Biol Psychiatry. 45:(8):1999;1030-1034.
10. Hamelin B.A., Bouayad A., Methot J., Jobin J., Desgagnes P., Poirier P., Allaire J., Dumesnil J., Turgeon J. Significant interaction between the nonprescription antihistamine diphenhydramine, and the CYP2D6 substrate metoprolol in health men with high or low CYP2D6 activity. Clin Pharmacol Ther. 67:(5):2000;466-477.
11. Dear Doctor Letter. Important changes to the prescribing information for mellaril (thioridazine HCL). 2000;Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. July 7.
12. Rosenberg K.P., Sildenafil J. Sex Marital Therapy. 25:1999;271-279.
13. DeBusk R., Drory Y., Goldstein I., et al. Management of sexual dysfunction in patients with cardiovascular disease recommendations of the Princeton Consensus Panel. Am J Cardiol. 86:2000;62F-68F.
14. Cheitlin M.D., Hutter A.M. Jr, Brindis R.G. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 33:1999;273-282.
15. Hammer J.S., Strain J.J., Friedberg A., Fulop G. Operationalizing a bedside pen entry notebook clinical database system in consultation-liaison psychiatry. Gen Hosp Psychiatry. 17:1995;165-172.
16. American Journal of Cardiovascular Drugs. Drugs, Devices, and Other Interventions. Adis International Inc. 860 Town Center Drive, Langhorne, PA 19047, USA.
17. Physicians' desk reference. 56th edition:2002;2689 Medical Economics Company, Inc, Montvale, NJ.